AstraZeneca FDA approval for breast-cancer drug supports sentiment
Citi says AstraZeneca’s U.S. Food and Drug Administration approval for breast-cancer drug Etcamah may matter more for investor sentiment than near-term revenue. The approval points to a relatively modest opportunity versus the larger market.
Story updates
02:36:02 PM UTC
SquawkNews
AstraZeneca is opening a new treatment paradigm in breast cancer with its Etcamah drug, which just got the green light from the U.S. Food and Drug Administration, Jefferies analysts say. This is arguably one of the most important approvals in breast cancer of the recent past, the analysts say. The…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.